DIMA Biotechnology Ltd. is a biotech company focusing on preclinical R&D products and services for druggable targets. We plan to complete the preparation of lead antibody molecules for all druggable targets in the next 3-5 years. We provide multiple pre-prepared lead antibody molecules for each target to help pharmaceutical companies skip the tedious steps of monoclonal antibody platform establishment and lead molecule screening. Therefore, companies can have more time to focus on the biological mechanism and developability study of drug targets, thus accelerating the process of new drug R&D.
Over the years, DIMA Biotech has been deeply engaged in developing and optimizing the underlying technology platforms for preclinical research. Currently, we have established two independently developed core technology platforms:1.Single/multiple transmembrane protein eukaryotic expression, preparation and purification platforms, apply mammalian cell expression systems, provide ECD or full-length membrane protein products closest to native conformation and functional validation. In addition, DIMA Biotech has developed five major functional full-length transmembrane protein preparation system, including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Synthetic Nanodisc. Thousands of drug target protein products are in stock. 2.DimAb® High-throughput single B-cell lead antibody molecule discovery platform. DIMA Biotech has completed the preparation and screening of lead antibody molecules against more than 200 drug targets by this platform in just two years. Moreover, we have formed strategic partnerships with several international pharmaceutical enterprises and licensed several drug target molecules. Our preclinical development strength is widely recognized by the industry. Our corporate culture is integrity, down-to-earth, innovation and focus，and our vision is to empower pharmaceutical enterprises in preclinical development and facilitate them to accelerate the process of new drug R&D.